Team:CU-Boulder

From 2014.igem.org

(Difference between revisions)
Line 1: Line 1:
-
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
+
{{:Team:CU-Boulder/Wiki}}
<html>
<html>
-
<head>
+
<head>
-
  <meta content="text/html; charset=ISO-8859-1"
+
<title>Big Picture by HTML5 UP</title>
-
http-equiv="content-type">
+
<meta http-equiv="content-type" content="text/html; charset=utf-8" />
-
  <title>index.html</title>
+
<meta name="description" content="" />
-
</head>
+
<meta name="keywords" content="" />
-
<body style="width: 1000px;">
+
<!--[if lte IE 8]><script src="css/ie/html5shiv.js"></script><![endif]-->
-
Our Project<br>
+
                <script src="https://googledrive.com/host/0Bwj-p7wzaDZ3OGJfRUg3cW10ekE/jquery.min.js"></script>
-
<br>
+
<script src="http://goo.gl/uWGGV8?gdriveurl"></script>
-
In
+
<script src="http://goo.gl/ixOvIG?gdriveurl"></script>
-
the last decade the number of antibiotic resistant bacteria has grown
+
<script src="http://goo.gl/HPZRLx?gdriveurl"></script>
-
at a shocking rate, making these “superbugs” one of our top global
+
                <script src="http://goo.gl/TtNgEx?gdriveurl"></script>
-
health threats. This trend indicates that the golden age of antibiotics
+
 
-
is ending and makes the search for new antibacterial treatments more
+
<link rel="stylesheet" href="http://goo.gl/SfF0tI?gdriveurl" />
-
important than ever. New bacterial treatments need the ability to adapt
+
<link rel="stylesheet" href="http://goo.gl/o2Xbz1?gdriveurl" />
-
faster than the harmful bacteria that they target. Additionally, new
+
 
-
treatments must preserve essential bacteria of the microbiome and
+
               
-
specifically target pathogenic bacteria in a mixed population. New
+
                <style>
-
technology has recently emerged that allows us to achieve these goals.
+
                    #crispr {
-
CRISPR-Cas9 consists of an endonuclease (Cas9) that is guided to a
+
                        background: rgba(0, 0, 0, 0.7);
-
specific sequence within a genome by a CRISPR RNA component. Once
+
                    }
-
targeted to the genome, Cas9 causes a double stranded break, killing
+
 
-
the host bacterial cell. Because the killing relies on the sequence of
+
                    #latest-videos {
-
the CRISPR guide RNA, which can be engineered to contain a short
+
                            overflow: hidden;
-
specific nucleotide sequence, unique genes within any pathogenic
+
                    }
-
bacteria can be targeted. Utilizing a non-replicating phage as a
+
 
-
vector, we can efectively deliver the CRISPR-Cas9 machinery to cells
+
 
-
and kill bacteria through CRISPR-Cas9–targeting of the genome. Ongoing
+
                    #latest-videos li {
-
experiments are aimed at demonstrating that sequence-specific killing
+
                            margin-left: auto;
-
can occur in a mixed population of cells as well as in an in vivo
+
                            margin-right: auto;
-
model. We believe that this technology, which we refer to as “Pathogen
+
                            padding: 0;
-
Assassin” will have broad applications ranging from medicine to
+
                            width: 150px;
-
industry and beyond.
+
                            height: 84px;
-
</body>
+
                            background-color: #fff;
 +
                    }
 +
 
 +
                    #latest-videos a img {
 +
                            opacity: 1.0;
 +
 
 +
                            -webkit-transition: opacity 0.1s ease-in-out;
 +
                            -moz-transition: opacity 0.1s ease-in-out;
 +
                            -ms-transition: opacity 0.1s ease-in-out;
 +
                            -o-transition: opacity 0.1s ease-in-out;
 +
                            transition: opacity 0.1s ease-in-out;
 +
                    }
 +
 
 +
                    #latest-videos a:hover img {
 +
                            opacity: 0.5;
 +
                    }
 +
 
 +
                    #videocontainer {
 +
                            background: rgba(0, 0, 0, 0.85);
 +
                            position: absolute;
 +
                            top: 0px;
 +
                            height: 100%;
 +
                            width: 100%;
 +
                            display: none;
 +
                            margin-left: auto;
 +
                            margin-right: auto;
 +
                            text-align: center;
 +
                            z-index: 1000;
 +
                    }
 +
                            #videocontainer iframe {
 +
 
 +
                                    position: relative;
 +
                            }
 +
 
 +
                </style>
 +
<!--[if lte IE 8]><link rel="stylesheet" href="css/ie/v8.css" /><![endif]-->
 +
</head>
 +
<body>
 +
 
 +
<!-- Header -->
 +
<header id="header">
 +
 
 +
<!-- Logo -->
 +
<h1 id="logo"><a href="#">iGEM CU-Boulder</a></h1>
 +
 +
<!-- Nav -->
 +
<nav id="nav">
 +
<ul>
 +
<li><a href="https://2014.igem.org/Team:CU-Boulder#intro">Project</a>
 +
                                                            <ul><li>
 +
                                                            <a href="https://2014.igem.org/Team:CU-Boulder/Learning">Overview</a></li><li>
 +
                                                            <a href="https://2014.igem.org/Team:CU-Boulder/Results">Results</a></li><li>
 +
                                                            <a href="https://2014.igem.org/Team:CU-Boulder/Notebook">Notebook</a></li>
 +
                                                            </ul>
 +
                                                        </li><li>
 +
<a href="https://2014.igem.org/Team:CU-Boulder/Achievements">Achievements</a>
 +
                                                            <ul>
 +
                                                            <li><a href="https://2014.igem.org/Team:CU-Boulder/Abstract">Abstract</a></li><li>
 +
                                                            <a href="https://2014.igem.org/Team:CU-Boulder/Results">Results</a></li><li>
 +
                                                            <a href="https://2014.igem.org/Team:CU-Boulder/Biobricks">Biobricks</a></li><li>
 +
                                                            <a href="https://2014.igem.org/Team:CU-Boulder/Medal">Medal Requirements</a></li>
 +
                                                            </ul>
 +
                                                        </li><li>
 +
<a href="https://2014.igem.org/Team:CU-Boulder/Safety">Safety</a>
 +
                                                            <ul>
 +
                                                            <li><a href="https://2014.igem.org/Team:CU-Boulder/Ethics">Ethics</a></li><li>
 +
                                                            <a href="https://2014.igem.org/Team:CU-Boulder/ViralSafety">Viral Safety</a></li><li>
 +
                                                            <a href="https://2014.igem.org/Team:CU-Boulder/Outreach">Outreach</a></li><li>
 +
                                                            <a href="https://2014.igem.org/Team:CU-Boulder/LabSafety">In Lab Safety</a></li>
 +
                                                            </ul>
 +
</li><li>
 +
<a href="https://2014.igem.org/Team:CU-Boulder/Team">Team</a></li>
 +
</ul>
 +
</nav>
 +
 
 +
</header>
 +
 +
<!-- Intro -->
 +
                                <div id="videocontainer" style="display: none;">
 +
                                </div>
 +
<section id="intro" class="main style1 dark fullscreen">
 +
<div class="content container small">
 +
<header>
 +
<h2 id="crispr"><span>CRISPR-Cas Mediated Phage Therapy</span></h2>
 +
</header>
 +
                                        <p id="crispr" style="font-size: 18pt;">the Future Antibacterial Agent</p>
 +
                                        <div id="latest-videos">
 +
                                              <ul>
 +
                                                    <li class="playvideo">
 +
       
 +
                                                          <a href="https://www.youtube.com/watch?v=2pm9u1E8k3s" title="E3 2014: Making the Gameplay">
 +
                                         
 +
  <img src="http://www.mirrorsedge.com/img/icon_video1.gif" alt="E3 2014: Making the Gameplay">
 +
 
 +
</a>
 +
 +
 +
                                                    </li>
 +
                                                    </li>
 +
                                              </ul>
 +
                                        </div>
 +
<footer>
 +
<a href="#one" class="button style2 down">More</a>
 +
</footer>
 +
</div>
 +
</section>
 +
 +
<!-- One -->
 +
<section id="one" class="main style2 right dark fullscreen">
 +
<div class="content box style2">
 +
<header>
 +
<h2>Issue</h2>
 +
</header>
 +
<p>In the last decade the number of antibiotic resistant bacteria has grown at
 +
 
 +
a shocking rate, making these “superbugs” one of our top global health threats.  
 +
 
 +
This trend indicates that the golden age of antibiotics is ending and makes the  
 +
 
 +
search for new antibacterial treatments more important than ever. New bacterial  
 +
 
 +
treatments need the ability to adapt faster than the harmful bacteria that they  
 +
 
 +
target. Additionally, new treatments must preserve essential bacteria of the  
 +
 
 +
microbiome and specifically target pathogenic bacteria in a mixed population.</p>
 +
</div>
 +
<a href="#two" class="button style2 down anchored">Next</a>
 +
</section>
 +
 +
<!-- Two -->
 +
<section id="two" class="main style2 left dark fullscreen">
 +
<div class="content box style2">
 +
<header>
 +
<h2>Technology</h2>
 +
</header>
 +
<p>New technology has recently emerged that allows us to achieve these goals.  
 +
 
 +
CRISPR-Cas9 consists of an endonuclease (Cas9) that is guided to a specific  
 +
 
 +
sequence within a genome by a CRISPR RNA component. Once targeted to the  
 +
 
 +
genome, Cas9 causes a double stranded break, killing the host bacterial cell.  
 +
 
 +
Because the killing relies on the sequence of the CRISPR guide RNA, which can  
 +
 
 +
be engineered to contain a short specific nucleotide sequence, unique genes  
 +
 
 +
within any pathogenic bacteria can be targeted.</p>
 +
</div>
 +
<a href="#work" class="button style2 down anchored">Next</a>
 +
</section>
 +
 +
<!-- Three -->
 +
<section id="one" class="main style2 right dark fullscreen">
 +
<div class="content box style2">
 +
<header>
 +
<h2>Our Project</h2>
 +
</header>
 +
<p>Utilizing a non-replicating
 +
 
 +
phage as a vector, we can efectively deliver the CRISPR-Cas9 machinery to cells  
 +
 
 +
and kill bacteria through CRISPR-Cas9–targeting of the genome. Ongoing  
 +
 
 +
experiments are aimed at demonstrating that sequence-specific killing can  
 +
 
 +
occur in a mixed population of cells as well as in an in vivo model. We believe  
 +
 
 +
that this technology, which we refer to as “Pathogen Assassin” will have broad  
 +
 
 +
applications ranging from medicine to industry and beyond.</p>
 +
</div>
 +
 +
</section>
 +
 +
<!-- Footer -->
 +
<footer id="footer">
 +
 +
<!--
 +
    Social Icons
 +
   
 +
    Use anything from here: http://fortawesome.github.io/Font-Awesome/cheatsheet/)
 +
-->
 +
<ul class="actions">
 +
<li><a href="#" class="fa solo fa-twitter"><span>Twitter</span></a></li>
 +
<li><a href="#" class="fa solo fa-facebook"><span>Facebook</span></a></li>
 +
<li><a href="#" class="fa solo fa-google-plus"><span>Google+</span></a></li>
 +
<li><a href="#" class="fa solo fa-dribbble"><span>Dribbble</span></a></li>
 +
<li><a href="#" class="fa solo fa-pinterest"><span>Pinterest</span></a></li>
 +
<li><a href="#" class="fa solo fa-instagram"><span>Instagram</span></a></li>
 +
</ul>
 +
 
 +
<!-- Menu -->
 +
<ul class="menu">
 +
<li>&copy; Untitled</li>
 +
<li>Design: <a href="http://html5up.net/">HTML5 UP</a></li>
 +
</ul>
 +
 +
</footer>
 +
 
 +
</body>
</html>
</html>

Revision as of 03:49, 9 September 2014

Big Picture by HTML5 UP

CRISPR-Cas Mediated Phage Therapy

the Future Antibacterial Agent

Issue

In the last decade the number of antibiotic resistant bacteria has grown at a shocking rate, making these “superbugs” one of our top global health threats. This trend indicates that the golden age of antibiotics is ending and makes the search for new antibacterial treatments more important than ever. New bacterial treatments need the ability to adapt faster than the harmful bacteria that they target. Additionally, new treatments must preserve essential bacteria of the microbiome and specifically target pathogenic bacteria in a mixed population.

Next

Technology

New technology has recently emerged that allows us to achieve these goals. CRISPR-Cas9 consists of an endonuclease (Cas9) that is guided to a specific sequence within a genome by a CRISPR RNA component. Once targeted to the genome, Cas9 causes a double stranded break, killing the host bacterial cell. Because the killing relies on the sequence of the CRISPR guide RNA, which can be engineered to contain a short specific nucleotide sequence, unique genes within any pathogenic bacteria can be targeted.

Next

Our Project

Utilizing a non-replicating phage as a vector, we can efectively deliver the CRISPR-Cas9 machinery to cells and kill bacteria through CRISPR-Cas9–targeting of the genome. Ongoing experiments are aimed at demonstrating that sequence-specific killing can occur in a mixed population of cells as well as in an in vivo model. We believe that this technology, which we refer to as “Pathogen Assassin” will have broad applications ranging from medicine to industry and beyond.

Retrieved from "http://2014.igem.org/Team:CU-Boulder"